Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.

"Disclosure statement : G.S.K. has received consultancy fees from Novartis Pharmaceuticals Corporation. G.S. has received grant/research support from Bristol Myers Squibb, Celgene, GSK, Eli Lilly and Novartis; is a consultant for AbbVie, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis and UCB; and has received speakers bureau fees from AbbVie, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis and Pfizer. P.G.C. has received consultancy fees or speakers bureau fees from AbbVie, Amgen, AstraZeneca, Eli Lilly, Galapagos, Gilead, GSK, Novartis, Pfizer and UCB. D.M. has received speaker fees and honoraria from Roche, Sobi and Novartis and has received research grants from Novartis. F.B. has received research grants from Pfizer, Janssen, Chugai, Celgene, Roche and GSK and consultation fees or speaker honoraria from Pfizer, Amgen, AbbVie, Sanofi, Eli Lilly, Novartis, Genzyme, Boehringer Ingelheim, Janssen, MSD, Celgene, Roche and Chugai. P.G. has received research grants, consultation fees or speaker honoraria from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Chugai, Janssen, Eli Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB. C.G. is an employee of Novartis Pharma AG, Basel, Switzerland. B.P. was an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, at the time of this analysis and is currently an employee of AbbVie. C.B. has received consultancy fees from and/or served on speakers bureaus for AbbVie, Novartis, Pfizer, Janssen, UCB, Eli Lilly and Sanofi Genzyme/Regeneron."

"Funding This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Disclosure statement: G.S.K. has received consultancy fees from Novartis Pharmaceuticals Corporation. G.S. has received grant/research support from Bristol Myers Squibb, Celgene, GSK, Eli Lilly and Novartis; is a consultant for AbbVie, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis and UCB; and has received speakers bureau fees from AbbVie, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis and Pfizer. P.G.C. has received consultancy fees or speakers bureau fees from AbbVie, Amgen, AstraZeneca, Eli Lilly, Galapagos, Gilead, GSK, Novartis, Pfizer and UCB. D.M. has received speaker fees and honoraria from Roche, Sobi and Novartis and has received research grants from Novartis. F.B. has received research grants from Pfizer, Janssen, Chugai, Celgene, Roche and GSK and consultation fees or speaker honoraria from Pfizer, Amgen, AbbVie, Sanofi, Eli Lilly, Novartis, Genzyme, Boehringer Ingelheim, Janssen, MSD, Celgene, Roche and Chugai. P.G. has received research grants, consultation fees or speaker honoraria from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Chugai, Janssen, Eli Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB. C.G. is an employee of Novartis Pharma AG, Basel, Switzerland. B.P. was an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, at the time of this analysis and is currently an employee of AbbVie. C.B. has received consultancy fees from and/or served on speakers bureaus for AbbVie, Novartis, Pfizer, Janssen, UCB, Eli Lilly and Sanofi Genzyme/Regeneron."

"Trial registration ClinicalTrials.gov, NCT02745080"